🇺🇸 FDA
Pipeline program

Dendritic cell immunotherapy

020221

Phase 3 small_molecule active

Quick answer

Dendritic cell immunotherapy for Glioblastoma Multiforme is a Phase 3 program (small_molecule) at NORTHWEST BIOTHERAPEUTICS INC with 1 ClinicalTrials.gov record(s).

Program details

Company
NORTHWEST BIOTHERAPEUTICS INC
Indication
Glioblastoma Multiforme
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials